#Mexico #Mexico City #financial results #2024 #Genomma Lab

Strong Performance in Genomma Lab's Financial Results for 2024

Genomma Lab Internacional Reports Stellar Q4 and Full-Year 2024 Results

MEXICO CITY, Feb. 26, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B), a leading player in the pharmaceutical and personal care sector in Mexico, has announced robust financial results for the fourth quarter and the entire year ended December 31, 2024. The figures released are prepared per International Financial Reporting Standards (IFRS) and are in nominal Mexican pesos.

Key Financial Highlights

Genomma Lab's CEO, Marco Sparvieri, commented on the company's remarkable achievements, stating that net sales soared by 32.4% in Q4 and 13.0% for the year. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin reached 24.0% in Q4, demonstrating a significant rise over the prior year's results. The company achieved a record free cash flow of Ps. 2.8 billion, marking a 36% increase over the previous period, and its earnings per share (EPS) doubled to 2.14.

The company has witnessed substantial growth in strategic markets such as the U.S., Mexico, Brazil, and Colombia, alongside a promising recovery in Argentina. Strong currency exchanges also contributed positively to the reported results. Moving forward, Genomma plans to strengthen its core brands, reinvesting savings generated from enhanced productivity in pursuit of their cost savings target of Ps. 1.8 billion by 2027.

Q4 and Full-Year Financial Summary

The financial summary reveals significant increases across various metrics, showcasing the company's operational effectiveness and market responsiveness. In Q4 2024, the company's net sales reached Ps. 4,665.6 million, a remarkable increase from Ps. 3,525.2 million in Q4 2023. Gross profit saw a 39.2% surge, with operating income rising by 44.9%. The company also noted a positive shift in net income, recording Ps. 473.5 million in Q4, after facing losses the previous year due to adverse currency fluctuations.

Financial Metrics	Q4 2024 (in million Ps)	% of Sales	Q4 2023 (in million Ps)	% of Sales	Year-Over-Year Growth (%)
----	-----	---	-----	---	-----
Net Sales	4,665.6	100.0%	3,525.2	100.0%	32.4%
Gross Profit	2,941.7	63.1%	2,112.7	59.9%	39.2%
Operating Income	1,013.1	21.7%	699.1	19.8%	44.9%
EBITDA	1,121.6	24.0%	723.8	20.5%	55.0%
Net Income	473.5	10.1%	-61.2	N/A	N/A
EPS	0.47		-0.06		N/A

The company achieved a significant increase in like-for-like sales by 3.5% in Q4 and 5.9% for the full year 2024, indicating a steady performance across its nine core categories.

Future Outlook

As Genomma Lab moves forward, it remains committed to leveraging the growth momentum of its brands and aims to capitalize on continued market expansion and increased efficiency. Their focus on core products, coupled with strategic reinvestments from productivity gains, will strengthen their positioning in the increasingly competitive landscape of the pharmaceutical and personal care markets.

CEO Marco Sparvieri emphasized the company's focus on sustainable growth, stating, "We will work diligently to consolidate our market positions and enhance profitability to ensure Genomma continues to thrive in the coming years."

For those interested in learning more about Genomma Lab's financial performance and strategies, a conference call will take place on February 27, 2025. Registration is available via the company’s investor relations page.

Genomma Lab, headquartered in Mexico, is known for its diverse range of premium branded products. The firm has built a strong reputation not only through its innovative approach towards product development but also through a strategic consumer-oriented marketing and widespread distribution network. The company's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB B."